This live session took place on Tuesday, May 23rd, 2017.
Global recession and consequent cuts in healthcare budgets have made it more difficult for innovative drugs to achieve market access, let alone premium pricing, in recent years. In response to this, payers and pharmaceutical companies have been searching for alternative funding formulas, in order to maximize public coverage of innovative pharmaceuticals, without breaking the bank for healthcare budgets. This is particularly crucial for drugs where clinical effectiveness and budgetary impact may be uncertain.
Simple managed entry agreements (MEAs) such as rebates and discounts have allowed for pharmaceutical manufacturers to provide discounts, without compromising the official list price and experiencing a negative knock-on effect due to international reference pricing (IRP). Furthermore, more innovative contracting types, such as risk-sharing agreements and performance-based schemes have allowed for payers and manufacturers to share the risks and uncertainties arising from premium-priced innovative agents and their use.
On the whole, these innovative contracts have allowed for innovative treatments to reach patients where there may not have been an avenue otherwise. Some countries have embraced this form of contracting more than others, but the overall use is on the rise worldwide and it is important for manufacturers to understand this phenomenon.
The webinar explores:
- What countries are on the forefront of using MEAs and in what indications?
- What kind of MEAs do payers prefer and why?
- Which aspects of MEAs are likely to have the greatest impact on your business?
- What new developments are in store for MEAs and what does this mean for industry?
- What will be the impact of innovative contracting on pricing and reimbursement?
- What strategies/lessons do we see translating to ex-European markets?
Presented by Yulia Privolnev, Principal Analyst, Market Access Insights